Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;7(4):219-31.
doi: 10.1038/nrendo.2010.217. Epub 2011 Jan 25.

Polycystic ovary syndrome: etiology, pathogenesis and diagnosis

Affiliations
Review

Polycystic ovary syndrome: etiology, pathogenesis and diagnosis

Mark O Goodarzi et al. Nat Rev Endocrinol. 2011 Apr.

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age, with a prevalence of up to 10%. Various diagnostic criteria have been proposed, generally centered around the features of hyperandrogenism and/or hyperandrogenemia, oligo-ovulation and polycystic ovarian morphology. Insulin resistance is present in a majority of cases, with compensatory hyperinsulinemia contributing to hyperandrogenism via stimulation of ovarian androgen secretion and inhibition of hepatic sex hormone-binding globulin production. Adipose tissue dysfunction has been implicated as a contributor to the insulin resistance observed in PCOS. Environmental and genetic factors also have a role in the development of PCOS. The syndrome is associated with numerous morbidities, including infertility, obstetrical complications, type 2 diabetes mellitus, cardiovascular disease, and mood and eating disorders. Despite these morbidities, PCOS may be common in our society owing to evolutionary advantages of the syndrome in ancient times, including smaller family sizes, reduced exposure to childbirth-related mortality, increased muscle mass and greater capacity to store energy. The diagnosis of PCOS hinges on establishing key features while ruling out other hyperandrogenic or oligo-ovulatory disorders. Treatment is focused on the goals of ameliorating hyperandrogenic symptoms, inducing ovulation and preventing cardiometabolic complications.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Obstet Gynecol. 2003 May;101(5 Pt 1):995-1007 - PubMed
    1. Hum Reprod. 2001 Feb;16(2):226-9 - PubMed
    1. Fertil Steril. 1990 May;53(5):785-91 - PubMed
    1. J Clin Invest. 1995 Jul;96(1):520-7 - PubMed
    1. J Clin Endocrinol Metab. 2004 Nov;89(11):5454-61 - PubMed

MeSH terms